Hodgkin Lymphoma Following Adalimumab for the Treatment of Crohn’s Disease in an Adolescent
暂无分享,去创建一个
[1] Á. Gutiérrez-Dalmau,et al. Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients , 2012, Drugs.
[2] O. O’Connor,et al. Targeting survival pathways in lymphoma. , 2010, Advances in experimental medicine and biology.
[3] B. Sands,et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[4] W. Bishop,et al. Initial clinical experience with allopurinol‐thiopurine combination therapy in pediatric inflammatory bowel disease , 2008, Inflammatory bowel diseases.
[5] A. Eggermont,et al. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.
[6] V. Annese,et al. Usefulness of ω-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: A double-blind, randomized, placebo-controlled study , 2005 .
[7] C. Brensinger,et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.
[8] V. Annese,et al. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. , 2005, World journal of gastroenterology.
[9] P. Macpherson,et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. , 2004, Blood.